Molecular Pathology of Cancer Group
2024 Activity indicators
- 4 national public competitive projects: ISCIII
- 2 private competitive projects led
- 5 private projects led
- 158 clinical led trials
- 71 publications
- IF: 664.00
- Q1 publications: 50 (70%)
- D1 publications : 28 (39%)
- 1 thesis
- 1 consensus document
- 5 acknowledgements to group members
- Evaluators of national public agency projects: 1 PI
- Members of national and international editorial committees: 1 PI
- 3 visitors hosted and 6.3 months stay:
- Universidad Politécnica de Madrid (spain)
- University Chieti-Pescara (Italy)
Milestones
- Coordination of the Breast Pathology Unit of the HURYC, contributing to obtaining its re-accreditation.
- Participation in the consensus guide for the use of biomarkers in breast cancer "Colomer R, GonzálezFarré B, Ballesteros AI, Peg V, Bermejo B, Pérez-Mies B, de la Cruz S, Rojo F, Pernas S, Palacios J. Biomarkers in breast cancer 2024: an updated consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology. Clin Transl Oncol. 2024; 26(12):2935-2951. doi: 10.1007/s12094-024-03541-1. PMID: 38869741".
- Stabilization of the cervical cancer screening program of the Community of Madrid (CERVICAM) and of the NGS project in solid tumors (ROM).
- Optimization of single-cell RNA seq in tissue fixed in formol and included in paraffin.
- Participation in collaborative research networks in cancer within the framework of CIBERONC.
Bibliometrics
| Article | Accum. FI | Mean FI | Articles Q1 or Q2 | % in Q1 or Q2 | Articles D1 | % on D1 | |
|---|---|---|---|---|---|---|---|
| 2020 | 17 | 69.25 | 4.07 | 12 | 71 | 5 | 29 |
| 2021 | 17 | 102.25 | 6.01 | 13 | 76 | 2 | 12 |
| 2022 | 25 | 149.83 | 5.99 | 18 | 72 | 6 | 24 |
| 2023 | 41 | 354.21 | 10.42 | 27 | 66 | 7 | 17 |
| 2024 | 71 | 664.00 | 10.38 | 61 | 86 | 28 | 39 |
| 171 | 1339.54 | 7.38 | 131 | 77 | 48 | 28 |
* Only original articles, editorials, guidelines & reviews
